Eli Lilly CEO Dave Ricks said upcoming Medicare coverage of obesity drugs could be a game-changer for the launch of its experimental weight-loss pill orforglipron, potentially expanding access to millions of patients even as competition with Novo Nordisk intensifies ahead of both companies’ earnings.
Importance Rank:
1
